Validity of skeletal muscle mass index measurements for assessing sarcopenia in patients with gynecological cancer.


Journal

Japanese journal of clinical oncology
ISSN: 1465-3621
Titre abrégé: Jpn J Clin Oncol
Pays: England
ID NLM: 0313225

Informations de publication

Date de publication:
05 Oct 2021
Historique:
received: 23 04 2021
accepted: 05 07 2021
pubmed: 31 7 2021
medline: 25 11 2021
entrez: 30 7 2021
Statut: ppublish

Résumé

The current study investigated an optimal method for using CT scan in detection of low skeletal muscle mass quantity (SMQ). In total, 82 consecutive patients with gynecological cancers were examined using computed tomography (CT) and dual-energy X-ray absorptiometry (DEXA) before treatment. Low SMQ was defined as a DEXA-based skeletal muscle mass index (SMI) of <5.40 kg/m2. Furthermore, CT-based SMI values were measured by six evaluators, and each evaluator measured SMI values two times for each subject. The first SMI value and the average SMI value were used for analyses. Receiver operating characteristic (ROC) analyses were performed to evaluate the performance of CT-based SMI measurements for detecting low SMQ. Interobserver agreement was assessed using the intraclass correlation coefficient (ICC). In total, 23 patients (28.0%) were diagnosed with low skeletal muscle mass. All areas under the curve (AUC) values from twelve (six evaluators × two measurements) ROC curves were within the range of 0.8-0.9. AUC values based on a single measurement and those based on two measurements were almost the same. The ICC was 0.828 (95% CI 0.777-0.874, P < 0.001) when using a single measurement value and increased to 0.959 (95% CI 0.944-0.971, P < 0.001) when using the average of the two measurements. A single measurement CT-based SMI efficiently identified patients with low SMQ in a daily clinical setting. The reliability of SMI measurements might be further improved by using a mean value of two measurements compared with the use of a single measurement value.

Sections du résumé

BACKGROUND BACKGROUND
The current study investigated an optimal method for using CT scan in detection of low skeletal muscle mass quantity (SMQ).
METHODS METHODS
In total, 82 consecutive patients with gynecological cancers were examined using computed tomography (CT) and dual-energy X-ray absorptiometry (DEXA) before treatment. Low SMQ was defined as a DEXA-based skeletal muscle mass index (SMI) of <5.40 kg/m2. Furthermore, CT-based SMI values were measured by six evaluators, and each evaluator measured SMI values two times for each subject. The first SMI value and the average SMI value were used for analyses. Receiver operating characteristic (ROC) analyses were performed to evaluate the performance of CT-based SMI measurements for detecting low SMQ. Interobserver agreement was assessed using the intraclass correlation coefficient (ICC).
RESULTS RESULTS
In total, 23 patients (28.0%) were diagnosed with low skeletal muscle mass. All areas under the curve (AUC) values from twelve (six evaluators × two measurements) ROC curves were within the range of 0.8-0.9. AUC values based on a single measurement and those based on two measurements were almost the same. The ICC was 0.828 (95% CI 0.777-0.874, P < 0.001) when using a single measurement value and increased to 0.959 (95% CI 0.944-0.971, P < 0.001) when using the average of the two measurements.
CONCLUSIONS CONCLUSIONS
A single measurement CT-based SMI efficiently identified patients with low SMQ in a daily clinical setting. The reliability of SMI measurements might be further improved by using a mean value of two measurements compared with the use of a single measurement value.

Identifiants

pubmed: 34327536
pii: 6330822
doi: 10.1093/jjco/hyab116
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1534-1540

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Ryutaro Yamada (R)

Division of Gynecologic Oncology, National Hospital Organization, Hokkaido, Sapporo, Japan.

Tomohiko Tsuruta (T)

Division of Gynecologic Oncology, National Hospital Organization, Hokkaido, Sapporo, Japan.

Yukiharu Todo (Y)

Division of Gynecologic Oncology, National Hospital Organization, Hokkaido, Sapporo, Japan.

Hiroyuki Kurosu (H)

Division of Gynecologic Oncology, National Hospital Organization, Hokkaido, Sapporo, Japan.

Kaoru Minowa (K)

Division of Gynecologic Oncology, National Hospital Organization, Hokkaido, Sapporo, Japan.

Shinichiro Minobe (S)

Division of Gynecologic Oncology, National Hospital Organization, Hokkaido, Sapporo, Japan.

Hiroko Matsumiya (H)

Division of Obstetrics and Gynecology, Obihiro Kosei General Hospital, Obihiro, Japan.

Hidenori Kato (H)

Division of Gynecologic Oncology, National Hospital Organization, Hokkaido, Sapporo, Japan.

Yoichi Mori (Y)

Division of Radiation Oncology, National Hospital Organization, Hokkaido, Sapporo, Japan.

Toshihisa Osanai (T)

Division of Orthopedic Surgery, National Hospital Organization, Hokkaido, Sapporo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH